Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Randomized, Active-controlled, Parallel, Open, Multi-center, Phase IV, Exploratory Clinical Trial to Compare the Effects of Improving the Carotid Artery Intima Media Thickness and Changing Lipid Levels by Cilostazol/Ginkgo Leaf Extract (Renexin CR) and Aspirin (Aspirin Protect Tab.) in Diabetic Peripheral Angiopathy.

NCT05906199 is registered in ClinicalTrials.gov with SK Chemicals Co., Ltd. as lead sponsor.

NCT NCT05906199
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05906199 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Randomized, Active-controlled, Parallel, Open, Multi-center, Phase IV, Exploratory Clinical Trial to Compare the Effects of Improving the Carotid Artery Intima Media Thickness and Changing Lipid Levels by Cilostazol/Ginkgo Leaf Extract (Renexin CR) and Aspirin (Aspirin Protect Tab.) in Diabetic Peripheral Angiopathy.
Lead sponsor
SK Chemicals Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
July 28, 2021
Completion date
December 13, 2023
Enrollment
105 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

diabetic peripheral angiopathy